The US Food and Drug Administration yesterday (May 29) approved two new oral drugs from UK pharma giant GlaxoSmithKline (LSE: GSK), Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with metastatic melanoma, the most dangerous type of skin cancer.
Tafinlar, a BRAF inhibitor, is cleared to treat patients with melanoma whose tumors express the BRAF V600E gene mutation. Mekinist, a MEK inhibitor, is approved to treat patients whose tumors express the BRAF V600E or V600K gene mutations. Approximately half of melanomas arising in the skin have a BRAF gene mutation. Tafinlar and Mekinist are being approved as single agents, not as a combination treatment.
The FDA approved Tafinlar and Mekinist with a genetic test called the THxID BRAF test, a companion diagnostic from France’s bioMerieux (Euronext: BIM), that will help determine if a patient’s melanoma cells have the V600E or V600K mutation in the BRAF gene.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze